BR0017332A - Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico - Google Patents

Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico

Info

Publication number
BR0017332A
BR0017332A BR0017332-0A BR0017332A BR0017332A BR 0017332 A BR0017332 A BR 0017332A BR 0017332 A BR0017332 A BR 0017332A BR 0017332 A BR0017332 A BR 0017332A
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
peptide
induction
nucleic acid
Prior art date
Application number
BR0017332-0A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Maria A Vitiello
Brian D Livingston
Esteban Celis
Ralph T Kubo
Howard M Grey
Robert W Chesnut
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of BR0017332A publication Critical patent/BR0017332A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"INDUçãO DE RESPOSTAS IMUNES CELULARES AO VìRUS DA HEPATITE B USANDO COMPOSIçõES DE PEPTìDEO E áCIDO NUCLéICO". Esta invenção utiliza nosso conhecimento dos mecanismos pelos quais o antígeno é reconhecido pelas células T para desenvolver vacinas a base de epítopo direcionadas ao HBV. Mais especificamente, este pedido apresenta nossa descoberta das composições farmacêuticas e processos de uso na prevenção e tratamento de infecção por HBV.
BR0017332-0A 2000-09-08 2000-09-08 Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico BR0017332A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/024802 WO2002019986A1 (en) 2000-09-08 2000-09-08 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions

Publications (1)

Publication Number Publication Date
BR0017332A true BR0017332A (pt) 2003-10-07

Family

ID=21741762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017332-0A BR0017332A (pt) 2000-09-08 2000-09-08 Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico

Country Status (10)

Country Link
US (1) US20070059799A1 (pt)
EP (1) EP1322288A4 (pt)
JP (1) JP2004508320A (pt)
KR (1) KR20030055261A (pt)
CN (1) CN1454082A (pt)
AU (1) AU7828100A (pt)
BR (1) BR0017332A (pt)
CA (1) CA2422506A1 (pt)
MX (1) MXPA03002035A (pt)
WO (1) WO2002019986A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
CA2500955A1 (en) * 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2005319578A1 (en) 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
WO2008005880A2 (en) * 2006-06-30 2008-01-10 Kim Laboratories Antibodies for norovirus
WO2008144675A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
NZ586074A (en) * 2010-06-10 2013-07-26 Auckland Uniservices Ltd LCLRP peptides, constructs and uses thereof
CN101979405A (zh) * 2010-08-27 2011-02-23 中国人民解放军第三军医大学 乙肝病毒核心抗原的免疫显性hla-a3超型限制性ctl表位及其鉴定方法和应用
CN102796172B (zh) * 2011-05-23 2015-03-25 中国科学院微生物研究所 一组乙型肝炎病毒特异型的hla_a33限制性表位肽及其应用
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
CN107001429B (zh) * 2014-11-28 2022-01-04 赛特瑞恩股份有限公司 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105727279B (zh) * 2016-03-25 2019-01-15 汪和睦 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN105727280B (zh) * 2016-03-25 2021-01-19 汪和睦 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107022006A (zh) * 2017-03-28 2017-08-08 东南大学 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽序列
CN110172080B (zh) * 2019-05-16 2022-05-24 南京大户生物科技有限公司 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
EP4069271A1 (en) 2019-12-07 2022-10-12 ISA Pharmaceuticals B.V. Treatment of diseases related to hepatitis b virus
EP3936867A1 (en) * 2020-07-06 2022-01-12 Imnate Sarl Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen
CN112725531B (zh) * 2021-01-20 2023-03-21 贵州中医药大学第二附属医院 一种mcda结合生物传感器的乙肝病毒快速检测系统
CN115960858B (zh) * 2022-08-24 2025-03-25 山东大学齐鲁医院 一种乙肝病毒特异性的肽段以及四聚体与检测乙肝病毒特异性cd8+t细胞的试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
WO1993021324A1 (en) * 1992-04-21 1993-10-28 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
EP1322288A4 (en) 2005-02-23
WO2002019986A1 (en) 2002-03-14
AU7828100A (en) 2002-03-22
KR20030055261A (ko) 2003-07-02
EP1322288A1 (en) 2003-07-02
CA2422506A1 (en) 2002-03-14
JP2004508320A (ja) 2004-03-18
MXPA03002035A (es) 2004-12-13
WO2002019986A9 (en) 2002-08-01
CN1454082A (zh) 2003-11-05
US20070059799A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
BR0017332A (pt) Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico
EP1246644A4 (en) HUMAN PAPILLOMAVIRUS CELLULAR IMMUNE RESPONSE INDUCED BY USE OF PEPTIDE COMPOSITIONS AND NUCLEIC ACID
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
BR9908599A (pt) Composições combinadas de vacina
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
ATE387214T1 (de) Impfstoff gegen bakterielle antigene
CO5070674A1 (es) Vacunas con un oligonucleotido cpg como adyuvante
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
BR0014282A (pt) Vacinas
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
EP1185545A4 (en) CD4-INDEPENDENT HIV ENVELOPE PROTEINS FOR USE AS VACCINES AND THERAPEUTIC AGENTS
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
DE69943042D1 (de) Herstellungsverfahren von dispergiermittel enthaltenden konzentrate mit hohem molekulargewicht
FI923020A0 (fi) Inte a inte b-sekvenser.
DE69937258D1 (de) Genetische impstoffe mit adjuvans
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
EP1366056A4 (en) PREPARATION OF DESOXYNUCLEOSIDES
ES2095258T3 (es) Nuevo virus de la enfermedad de la bolsa infecciosa.
DE68927340D1 (de) Biologischer impfstoff, wirksam gegen aphanomyces
PT1149901E (pt) Mutantes de pestivirus e vacinas contendo os mesmos
RU2001127052A (ru) Штамм вируса Эбола "Заир Ч-15" для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов
ATE153375T1 (de) Von menschlichen neuroblastomazellen erreichbares virus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/005 (2006.01), A61K 38/00 (2006.01), A61K